Interferon‐α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study

BACKGROUND. RUNX1‐RUNX1T1 transcript levels were established as a powerful marker for predicting relapse in patients with t(8;21) acute myeloid leukemia (AML). We aimed to identify the efficacy of minimal residual disease (MRD)‐directed interferon‐alpha (IFN‐α) treatment in patients with t(8;21) AML...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Mo, Xiao‐Dong, Wang, Yu, Zhang, Xiao‐Hui, Xu, Lan‐Ping, Yan, Chen‐Hua, Chen, Huan, Chen, Yu‐Hong, Qin, Ya‐Zhen, Liu, Kai‐Yan, Huang, Xiao‐Jun
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2018
Matèries:
Hematologic Malignancies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291331/
https://ncbi.nlm.nih.gov/pubmed/30076280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0692
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars